Effect on mood of subthalamic DBS for Parkinson’s disease A consecutive series of 24 patients

Berney, Alexandre; Vingerhoets, François; Perrin, Andrew J.; Guex, Patrice; Villemure, Jean‐Guy; Burkhard, Pierre; Benkelfat, Chawki; Ghika, Joseph

doi:10.1212/01.wnl.0000032756.14298.18

Cited by 299 publications

(186 citation statements)

References 9 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…There is evidence that DBS may also worsen depression and mania, increase apathy, affect emotional lability, and increase the risk of suicide (Berney et al, 2002;Doshi et al, 2002;Okun et al, 2003Okun et al, , 2009Funkiewiez et al, 2004;Smeding et al, 2005Smeding et al, , 2006Drapier et al, 2008;Voon et al, 2008). Mood problems are more common in patients treated with STN-DBS than those treated with GPi-DBS Follett et al, 2010;Moro et al, 2010;Bronstein et al, 2011).…”

Section: Non-motor Side Effects Of Stn and Gpi-dbsmentioning

confidence: 99%

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

Smith

Wichmann

Factor

et al. 2011

Neuropsychopharmacol

194

137

View full text Add to dashboard Cite

The demonstration that dopamine loss is the key pathological feature of Parkinson's disease (PD), and the subsequent introduction of levodopa have revolutionalized the field of PD therapeutics. This review will discuss the significant progress that has been made in the development of new pharmacological and surgical tools to treat PD motor symptoms since this major breakthrough in the 1960s. However, we will also highlight some of the challenges the field of PD therapeutics has been struggling with during the past decades. The lack of neuroprotective therapies and the limited treatment strategies for the nonmotor symptoms of the disease (ie, cognitive impairments, autonomic dysfunctions, psychiatric disorders, etc.) are among the most pressing issues to be addressed in the years to come. It appears that the combination of early PD nonmotor symptoms with imaging of the nigrostriatal dopaminergic system offers a promising path toward the identification of PD biomarkers, which, once characterized, will set the stage for efficient use of neuroprotective agents that could slow down and alter the course of the disease.

show abstract

Section: Non-motor Side Effects Of Stn and Gpi-dbsmentioning

confidence: 99%

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

Smith

Wichmann

Factor

et al. 2011

Neuropsychopharmacol

194

137

View full text Add to dashboard Cite

show abstract

“…In addition to improving motor function, some studies have also found DBS to be associated with improvements in mood and depression [40,41,42]. The results of these studies are equivocal, however, as some reports have demonstrated adverse reactions, including significant worsening of depressive symptoms and suicidal ideation [41,43,44] and inducement of mania [45,46,47]. In addition, a randomized, controlled trial of Qigong exercise showed decreases in depression scores in both the control and treatment group, although those in the treatment group did experience a greater improvement in motor symptoms [48].…”

Section: Depression and Parkinson's Diseasementioning

confidence: 99%

CBT for the treatment of depression in Parkinson’s disease: a promising nonpharmacological approach

Dobkin¹,

Menza²,

Bienfait³

2008

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Depression is very common in PD and linked with a faster progression of physical symptoms, greater cognitive decline, and poorer quality of life. Non-pharmacological approaches, like cognitivebehavioral therapy (CBT), for the treatment of depression in Parkinson's disease (dPD) have received little experimental attention despite strong demonstrated efficacy in other geriatric and medical populations. Depressed PD patients often differ from the depressed non-PD elderly in that they present with increased rates of both executive dysfunction and co-morbid psychiatric diagnoses, may differ in their depressive symptom presentation, and typically have caregivers who are highly involved in their treatment. Therefore, it is not possible to conclude that empirically validated treatments in the depressed aged will generalize to those with Parkinson's disease. In order to be most effective for PD patients, CBT should be tailored to their unique needs. Additional controlled research is needed to further explore the efficacy of CBT for dPD.

show abstract

“…The resulting signs and symptoms of inappropriate stimulation may be recognized when they differ from the condition being treated by DBS. A variety of negative effects have been described, including depression, 13 suicidality, 14 apathy, 15 mania, 16 anxiety, 17 hypersexuality, 18 and aggressiveness. 19 These symptoms generally occur soon after adjustment of the DBS and thus may occur months to years after implantation.…”

Section: Stimulation Side Effectsmentioning

confidence: 99%

Severe agitation following deep brain stimulation for parkinsonism

Rose

Mostrenko

McMaster

et al. 2011

CJEM

View full text Add to dashboard Cite

The use of deep brain stimulation has become increasingly common for the treatment of movement disorders, including Parkinson disease. Although deep brain stimulation is generally very successful in alleviating the extrapyramidal symptoms of Parkinson disease, side effects can occur. This case report describes a patient presenting to the emergency department in a state of extreme aggression 3 days after a change in the parameters of his bilateral subthalamic nucleus stimulator. We review the complications of deep brain stimulation relevant to the emergency physician and provide some practical information on stimulator adjustment in an emergency. RÉ SUMÉIl est de plus en plus courant d'utiliser la stimulation cé ré brale profonde pour traiter les troubles du mouvement, y compris la maladie de Parkinson. Bien que cette technique donne gé né ralement de trè s bons ré sultats pour atté nuer les symptô mes extrapyramidaux de la maladie de Parkinson, des effets secondaires peuvent se produire. Nous pré sentons le cas d'un patient qui s'est pré senté à l'urgence dans un é tat d'extrê me agressivité trois jours aprè s un changement aux paramè tres des é lectrodes de stimulation bilaté rale du noyau sous-thalamique. Nous passons en revue les complications de la stimulation cé ré brale profonde pertinentes pour le mé decin d'urgence et fournissons de l'information pratique sur le ré glage du stimulateur en urgence.

show abstract

Effect on mood of subthalamic DBS for Parkinson’s disease A consecutive series of 24 patients

Cited by 299 publications

References 9 publications

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa

CBT for the treatment of depression in Parkinson’s disease: a promising nonpharmacological approach

Severe agitation following deep brain stimulation for parkinsonism

Contact Info

Product

Resources

About